Please login to the form below

Not currently logged in
Email:
Password:

mirabegron

This page shows the latest mirabegron news and features for those working in and with pharma, biotech and healthcare.

Germany’s IQWiG denies Astellas’ incontinence drug

Germany’s IQWiG denies Astellas’ incontinence drug

IQWiG, which assesses the cost-effectiveness of treatments for reimbursement in Germany, published an evaluation of Astellas' Betmiga (mirabegron) that does not recommend its use in the treatment of overactive bladder

Latest news

  • Astellas gets first OK for prostate drug Vesomni Astellas gets first OK for prostate drug Vesomni

    The company has already added to its OAB franchise with the approval of Myrbetriq/Betanis (mirabegron) in Japan in 2011 and the US last year, and has said in the past

  • NICE recommends Astellas' Betmiga for overactive bladder NICE recommends Astellas' Betmiga for overactive bladder

    The National Institute for Health and Care Excellence (NICE) said in final draft guidance that Astellas' Betmiga (mirabegron) was an efficient use of NHS resources to treat people with overactive bladder ... Offering mirabegron as an option for treatment,

  • European approval for Astellas' first-in-class bladder drug Betmiga

    Will compete with Pfizer's Detrol and Astellas' own Vesicare. The European Commission has approved Astellas' overactive bladder treatment Betmiga (mirabegron).

  • Range of approvals in Japan

    Tokyo-based Astellas also received news of Japanese approvals, including Betanis (mirabegron) for use in the treatment of overactive bladder, and Recalbon (minodronic acid hydrate) for use in osteoporosis.

  • Astellas posts positive bladder therapy data

    Astellas has reported positive data from a phase III trial for its overactive bladder therapy candidate mirabegron. ... Mirabegron is a selective beta-3 adrenoceptor antagonist designed to facilitate filling of the bladder and storage of urine.

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new

  • Interview: Ken Jones, Astellas Pharma Europe Interview: Ken Jones, Astellas Pharma Europe

    Urology is a key strategic area for Astellas and we have a strong pipeline in this therapy area; we are currently getting prepared with Mirabegron, a drug to treat overactive bladder,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics